Castle Biosciences, Inc. (CSTL)
| Market Cap | 496.89M |
| Revenue (ttm) | 347.08M |
| Net Income (ttm) | -5.07M |
| Shares Out | 28.87M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 583,072 |
| Open | 17.02 |
| Previous Close | 17.05 |
| Day's Range | 16.75 - 17.51 |
| 52-Week Range | 15.70 - 35.84 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 38.33 (+122.72%) |
| Earnings Date | May 5, 2025 |
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose me... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is $38.33, which is an increase of 122.72% from the latest price.
News
Castle Biosciences Celebrates Skin Cancer Awareness Month
Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month
Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations and Corporate Affairs Derek ...
Castle Biosciences Reports First Quarter 2025 Results
Q 1 2025 revenue increased 21% over Q 1 2024 to $88 million Q 1 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, DecisionDx ® -SCC, TissueCypher ®) increased 33% over Q 1...
Castle Biosciences to Acquire Previse
Expected to complement Castle's current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development F...
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help Pr...
New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines' 5% threshold to fo...
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
FRIENDSWOOD, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its achieve...
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research int...
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
FRIENDSWOOD, Texas, April 08, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key education...
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has...
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test
Consistent with prior studies, published results from Castle's DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivit...
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress.
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantl...
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting.
Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, Pres...
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #diagnostics--Castle Biosciences, Inc. (Nasdaq: CSTL), today announced its financial results for the fourth quarter and year ended December 31, 2024.
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management is scheduled to present a company overview at two investor conferences next month.
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of GEP tests at the 2025 Winter Clinical Dermatology Conference - Hawaii,...
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the fourth quarter and year ended Dec. 31, 2024, after the close of market on Thursday, ...
Castle's Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of tests for skin cancer through poster presentations at the Maui Derm Ha...
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary...
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--Castle Biosciences has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett's Es...
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis.
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's Compensation Committee of its Board of Directors granted restricted stock units (RSUs) as inducement material to new employee...
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Meta-analysis concludes DecisionDx-Melanoma provides improved risk stratification over staging alone to inform personalized management of melanoma.